Catalyst Pharmaceuticals, Inc. (CPRX.D)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $31.49
- As of
Kresmion compiles this page from CPRX.D's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
CATALYST PHARMACEUTICALS, INC. (CPRX.D): 7 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-07-16.
See the full CPRX.D dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for CPRX.D on one page. Preview it with sample data, then open it live with a free account.
Preview the CPRX.D dossierActive signals for CPRX.D
No recent signals on CPRX.D in the last 180 days.
FREE, NO ACCOUNT
Every signal on CPRX.D, as it fires
New filings, 13F moves and cross asset signals on CPRX.D land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in CPRX.D (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 14888U101 · 2026Q2 | $67.1M | 0.09% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 14888U101 · 2026Q2 | $33.6M | 0.01% | , |
| SOROS FUND MANAGEMENT LLCCUSIP 14888U101 · 2026Q2 | $10.8M | 0.13% | , |
| Point72 Asset Management, L.P.CUSIP 14888U101 · 2026Q2 | $5.5M | 0.01% | , |
| D. E. Shaw & Co., Inc.CUSIP 14888U101 · 2026Q2 | $4.2M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 14888U101 · 2026Q2 | $2.7M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 14888U101 · 2026Q2 | $954K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, CPRX.D
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
CPRX.D against its peers
CPRX.D's operating margin of 43.8% ranks in the 90th percentile of 14 Biotechnology sub-industry peers, fiscal periods ending between 2025-11-30 and 2025-12-31.
| Metric | CPRX.D | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 589M USD | 84.0M USD | 75 | 17 |
| Gross margin | 85.2% | 80.2% | 50 | 6 |
| Operating margin | 43.8% | -43.1% | 90 | 14 |
| Net margin | 36.4% | -40.4% | 83 | 14 |
| Return on equity | 22.5% | -30.3% | 90 | 23 |
Peers (24): TNGX, RLAY, ARQT, VCYT, LEGN, TLX, EWTX, ACAD, DNTH, XENE, GRTX.D, VKTX, IDYA, CELC, DFTX, CRSP, IRON, SRRK, ERAS, ORKA, TVTX, PTCT, DNLI, NRIX. Left out: PBLS (no annual filing). Fiscal periods ending between 2025-11-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (CPRX.D: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow CPRX.D on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to CPRX.D for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.